DBV Technologies S.A. (ENXTPA: DBV)
Health Care · Biotechnology · FR
€1.68
-11.87% today · -35.2% 1Y
DBV Technologies S.A. (ENXTPA: DBV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $555.98M and employs 170 people.
Over the last twelve months the share price has lost 35.2%, trading between 1.68 and 4.50.
Tweenvest scores DBV Technologies S.A. across four factors: quality 37/100, value 50/100, growth 0/100. Its strongest factor is value.
DBV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $555.98M
- Revenue (TTM)
- $5.04M
- P/E
- —
- EPS
- -0.60
- Dividend yield
- —
- Beta (5Y)
- -0.24
- 52-week high
- €4.50
- 52-week low
- €1.68
- Avg volume (3M)
- —
- Shares outstanding
- 295.92M
- Employees
- 170
- Next earnings
- —
About DBV Technologies S.A.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
- ISIN
- FR0010417345
- Founded
- 2002
- Listed since
- Mar 29, 2012
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pharmicell Co., Ltd.KOSE: A005690 | $573.98M | ₩12,860.00 | +3.71% |
| Shanghai Serum Bio-Technology Co., Ltd.SHSE: 688163 | $563.39M | CN¥34.87 | -12.83% |
| Shanghai MicuRx Pharmaceutical Co., Ltd.SHSE: 688373 | $561.38M | CN¥5.73 | -0.87% |
| Zhejiang Orient Gene Biotech Co., LtdSHSE: 688298 | $557.20M | CN¥19.50 | +0.67% |
| Jacobio Pharmaceuticals Group Co., Ltd.SEHK: 1167 | $555.24M | HK$5.57 | -7.40% |
| Jiangsu Sihuan Bioengineering Co., LtdSZSE: 000518 | $553.35M | CN¥3.60 | +0.28% |
| Thalys Medical Technology Group CorporationSHSE: 603716 | $545.42M | CN¥16.47 | -0.90% |
| TransThera Sciences (Nanjing), Inc.SEHK: 2617 | $541.29M | HK$10.43 | -2.71% |
Figures last refreshed Oct 11, 2026.